Skip to main content
JAMA Network logoLink to JAMA Network
. 2023 Jul 17;6(7):e2323879. doi: 10.1001/jamanetworkopen.2023.23879

Presence and Quantity of Botanical Ingredients With Purported Performance-Enhancing Properties in Sports Supplements

Pieter A Cohen 1,2,, Bharathi Avula 3, Kumar Katragunta 3, John C Travis 4, Ikhlas Khan 3
PMCID: PMC10352857  PMID: 37459101

Abstract

This case series study examines the accuracy of labels of dietary sports supplements containing botanical ingredients.

Introduction

Since the US Food and Drug Administration (FDA) banned ephedra from dietary supplements in 2004, supplement manufacturers have promoted a complex variety of alternative botanical compounds for sports enhancement. Extracts of Rauwolfia vomitoria containing α-yohimbine, the caffeine-like compound methylliberine, the partial β2-agonist halostachine, the plant steroid turkesterone, and norepinephrine-like octopamine are all found in plants and are promoted in dietary supplements for their stimulant or anabolic effects.1,2,3

The FDA does not preapprove these ingredients, or any supplement ingredient, for either efficacy or safety before their introduction, but FDA inspections have found that supplement manufacturers often fail to comply with basic manufacturing standards, such as establishing the identity, purity, or composition of the final product. Given the products’ potentially complex physiologic effects and concerns regarding manufacturing quality, we determined the accuracy of dietary supplement labels declaring R vomitoria, methylliberine, halostachine, octopamine, and turkesterone.

Methods

Dietary supplement products were included in this case series if they were labeled as containing 1 of the following ingredients: R vomitoria, methylliberine, turkesterone, halostachine, or octopamine. All products were purchased online, and products were excluded if the actual label did not list 1 of the 5 ingredients. Powder from the dietary supplement products was reconstituted in methanol and analyzed for the presence and quantity of the 5 ingredients and FDA-prohibited ingredients by liquid chromatography quadrupole time-of-flight mass spectrometry. See the eAppendix in Supplement 1 for additional details.

Results

Of the 63 products purchased, 6 did not list 1 of the 5 ingredients on the label; therefore, 57 products were analyzed (13 listing R vomitoria; 21, methylliberine; 8, turkesterone; 7, halostachine; and 8, octopamine). Twenty-three of 57 products (40%) did not contain a detectable amount of the labeled ingredient. Of the products that contained detectable amounts of the listed ingredient, the actual quantity ranged from 0.02% to 334% of the labeled quantity (Table). Six of 57 products (11%) contained a quantity of the ingredient within 10% of the labeled quantity.

Table. Presence and Quantity of Botanical-Based Ingredients in Dietary Supplements.

Product code Claim on label Labeled ingredient and amount per serving size Measured ingredients per serving size, mean (SD), mg Measured vs labeled ingredient per serving size, % Prohibited ingredients detected Prohibited ingredients per serving size, mean (SD), mg
Rauwolfia vomitoria productsa
A1 Nootropic, limitless energy R vomitoria root-bark extract 2.5 mg ND 0 Omberacetam (Noopept)b,c 5 (0.01)
B1 Fat burner R vomitoria root extract ND NP Octodrinec,d 319 (0.001)
C1 Thermogenic R vomitoria extract (root bark) ND NP ND NA
D1 Preworkout R vomitoria root extract ND NP 1,4-DMAAe,f 2.3 (0.01)
E1 Thermogen, precardio powerhouse, fat loss, energy, motivation R vomitoria root-bark extract ND NP ND NA
F1 Preworkout R vomitoria root extract 1.5 mg ND 0 ND NA
G1 Energy, aggression R vomitoria extract (root-bark) ND NP ND NA
H1 Preworkout R vomitoria root extract 1.5 mg ND 0 ND NA
I1 Preworkout R vomitoria root extract 1.0 mg ND 0 ND NA
J1 No claim R vomitoria root extract 1.0 mg ND 0 ND NA
K1 Preworkout R vomitoria extract (root-bark) 225 µg ND 0 ND NA
L1 Weight loss, fat incinerator R vomitoria extract (root-bark) 225 µg ND 0 1,4-DMAAe,f 0.5 (0.01)
M1 Preworkout R vomitoria extract (root-bark) ND NP ND NA
Methylliberine products
N1 Thermo activator, energy, focus Methylliberine 25 mg 33 (0.2) 133 ND NA
O1 Energy, focus Methylliberine 130 (0.2) NP ND NA
P1 Metabolism optimization Methylliberine 100 mg 125 (0.8) 125 ND NA
Q1 Preworkout Methylliberine 40 mg 52 (0.2) 129 ND NA
R1 Preworkout Methylliberine 100 mg 61 (0.3) 61 ND NA
S1 Preworkout Methylliberine 100 mg 136 (0.5) 136 ND NA
T1 No claim Methylliberine 16 (0.5) NP ND NA
U1 Preworkout Methylliberine 40 mg 59 (0.2) 147 ND NA
V1 Energizing nootropic Methylliberine 40 mg 134 (0.2) 334 ND NA
W1 Preworkout Methylliberine 25 mg 43 (0.02) 174 ND NA
X1 Metabolic accelerator Methylliberine 50 mg 69 (0.5) 138 ND NA
Y1 Mind boosting nootropic Methylliberine 75 mg 76 (0.3) 101 ND NA
Z1 Fat burner Methylliberine 100 mg 111 (0.3) 111 ND NA
A2 Nootropic, mental concentration Methylliberine 50 mg 68 (0.1) 136 ND NA
B2 Metabolism booster Methylliberine 25 mg 29 (0.6) 114 ND NA
C2 Fast acting energy, mood, focus Methylliberine 125 mg 133 (0.5) 106 ND NA
D2 No claim Methylliberine 40 mg 56 (0.2) 139 ND NA
E2 No claim Methylliberine 76 (0.2) NP ND NA
F2 No claim Methylliberine 150 mg 171 (0.1) 114 ND NA
G2 No claim Methylliberine 100 mg 115 (0.3) 115 ND NA
H2 No claim Methylliberine 100 mg 100 (0.1) 100 ND NA
Turkesterone productsg
I2 Protein synthesis, enhance strength, increase lean mass Ajuga turkestanica extract (10% turkesterone) 500 mg 0.01 (0.003) 0.02 ND NA
J2 Bodybuilding Turkesterone 500 mg ND 0 ND NA
K2 No claim A turkestanica extract (turkesterone) whole plant 0.02 (0.004) NP ND NA
L2 No claim A turkestanica extract (10% turkesterone) 550 mg ND 0 ND NA
M2 No claim A turkestanica extract (10% turkesterone) 500 mg 0.1 (0.0) 0.1 ND NA
N2 Premium muscle growth A turkestanica extract (standard minimum 10% turkesterone) 300 mg 0.03 (0.01) 0.1 ND NA
O2 Testosterone anabolic support A turkestanica extract (10% turkesterone) ND NP ND NA
P2 Bodybuilding Turkesterone 500 mg ND 0 ND NA
Halostachine productsh
Q2 Intense, sustained thermogenic effect Halostachine HCl ND NP Deterenolc,i 0.02 (0.001)
Oxilofrinec,j 0.2 (0.02)
1,4-DMAAe,f 10 (0.1)
Octodrined,f 0.8 (0.02)
R2 Highly potent fat burner Halostachine (Halostachys capsica) 40 mg 0.5 (0.1) 1.3 ND NA
S2 Preworkout Halostachine 2.0 (0.2) NP Deterenolc,i 0.01 (0.001)
T2 Stimulant H capsica (aerial parts) extract 30 mg ND NP ND NA
U2 Preworkout Halostachine 40 mg 1.0 (0.2) 3.0 Deterenolc,i 0.04 (0.001)
V2 Preworkout Halostachine 100 mg 3.0 (0.1) 2.7 ND NA
W2 Preworkout H capsica (aerial parts) extract (standard to 80% halostachine) 100 mg ND 0 ND NA
Octopamine productsh
X2 Preworkout intensifier Octopamine 30 mg 28 (0.1) 94.3 ND NA
Y2 Preworkout Octopamine ND NP ND NA
Z2 Nootropic brain fuel Octopamine 30 mg 28 (0.2) 94 ND NA
A3 Stimulant, weight loss Octopamine 0.2 (0.1) NP ND NA
B3 Fat loss Octopamine 21 (0.1) NP ND NA
C3 Weight management Octopamine ND NP ND NA
D3 Appetite suppressor, thermogenic ignitor, fat incinerator Octopamine ND NP ND NA
E3 Far burner Octopamine 5 mg 6 (0.1) 110 ND NA

Abbreviations: 1,4-DMAA, 1,4-dimethylamylamine; NA, not applicable; ND, not detected; NP, not possible (estimate not possible given lack of declared quantity of ingredient on label).

a

R vomitoria extract was considered not detected if analyses did not detect at least 5 common R vomitoria alkaloids (ie, rauwolsine, ajmaline, serpentinine, yohimbine, and reserpine), with a limit of detection of 10 ng/mL for each alkaloid.

b

The mechanism of action of omberacetam is unknown; it is marketed in Russia as Noopept. The drug has never been approved for use in the US.

c

Ingredient is declared on label.

d

Octodrine was marketed as part of a multicomponent oral medication in Germany. The drug has never been approved for oral use in the US.

e

1,4-DMAA is an analogue of 1,3-dimethylamylamine, a sympathomimetic amine introduced in nasal inhalers in the 1940s in the US. 1,4-DMAA has never been approved as a medication for use in the US or elsewhere.

f

The ingredient was not declared on the label.

g

For turkesterone products, ND means not detected, with a limit of detection of 25 ng/mL.

h

For halostachine and octopamine products, ND means not detected, with a limit of detection of 50 ng/mL.

i

Deterenol is a β-agonist that was formerly available in Europe as an ophthalmologic preparation for the treatment of glaucoma. It has never been approved for use by the US Food and Drug Administration.

j

Oxilofrine is a pharmaceutical drug developed in Europe in the 1930s with cardiac stimulatory effects similar to ephedrine. The drug has never been approved for use by the US Food and Drug Administration.

Seven of 57 products (12%) were found to contain at least 1 FDA-prohibited ingredient (Table). Five different FDA-prohibited compounds were found, including 4 synthetic simulants, 1,4-dimethylamylamine, deterenol, octodrine, oxilofrine, and omberacetam. Six products contained 1 of these prohibited ingredients, and 1 product contained 4 different prohibited ingredients.

Discussion

Eighty-nine percent of dietary supplement labels did not accurately declare the ingredients found in the products, and 12% of products contained FDA-prohibited ingredients. A prior study4 of dietary supplements, before the FDA ephedra ban, found that 6 of 12 products (50%) contained ephedra within 10% of the labeled amount. In a more recent study5 of caffeine content of sports supplements, 9 of 20 products (45%) contained a quantity of caffeine within 10% of the labeled quantity. In the current study, which to our knowledge is the first to quantify these 5 supplement ingredients, only 11% of products were accurately labeled and 5 different FDA-prohibited ingredients were found, including an unapproved drug available in Russia (ie, omberacetam), 3 drugs formerly available in Europe (ie, octodrine, oxilofrine, and deterenol), and 1 drug that has never been approved in any country (ie, 1,4-dimethylamylamine).6

The study has limitations, including that the sample size was small, only 1 sample of each brand was analyzed, and only supplements containing 1 of 5 targeted ingredients were analyzed. It is not known whether the results are generalizable to other botanical ingredients in sports supplements or whether quantities might also vary among batches within a given brand. Given these findings, clinicians should advise consumers that supplements listing botanical ingredients with purported stimulant or anabolic effects may not be accurately labeled and may contain FDA-prohibited drugs.

Supplement 1.

eAppendix. Supplemental Methods

eReferences

Supplement 2.

Data Sharing Statement

References

  • 1.Wang N, Xie YW, Li MY, et al. Simultaneous determination of five alkaloids from Rauvolfia vomitoria in rat plasma by LC-MS/MS: application to a comparative pharmacokinetic study in normal and type 2 diabetic rats. J Sep Sci. 2021;44(7):1391-1403. doi: 10.1002/jssc.202000914 [DOI] [PubMed] [Google Scholar]
  • 2.Wang YH, Mondal G, Butawan M, Bloomer RJ, Yates CR. Development of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for characterizing caffeine, methylliberine, and theacrine pharmacokinetics in humans. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1155:122278. doi: 10.1016/j.jchromb.2020.122278 [DOI] [PubMed] [Google Scholar]
  • 3.Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-615. doi: 10.1002/bmc.1705 [DOI] [PubMed] [Google Scholar]
  • 4.Haller CA, Duan M, Benowitz NL, Jacob P III. Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements. J Anal Toxicol. 2004;28(3):145-151. doi: 10.1093/jat/28.3.145 [DOI] [PubMed] [Google Scholar]
  • 5.Cohen PA, Attipoe S, Travis J, Stevens M, Deuster P. Caffeine content of dietary supplements consumed on military bases. JAMA Intern Med. 2013;173(7):592-594. doi: 10.1001/jamainternmed.2013.3254 [DOI] [PubMed] [Google Scholar]
  • 6.Cohen PA, Travis JC, Vanhee C, Ohana D, Venhuis BJ. Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine. Clin Toxicol (Phila). 2021;59(11):975-981. doi: 10.1080/15563650.2021.1894333 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplement 1.

eAppendix. Supplemental Methods

eReferences

Supplement 2.

Data Sharing Statement


Articles from JAMA Network Open are provided here courtesy of American Medical Association

RESOURCES